

Provided by: Mycenax Biotech Inc.

Financial year: Yearly

Unit: NT\$ thousand

Accounting Title	2019/06/30	2018/12/31	2018/06/30
Balance Sheet			
Current assets			
Cash and cash equivalents	449,967	215,745	359,385
Current financial assets at amortised cost	29,473	88,599	114,917
Current contract assets	17,417	5,501	0
Accounts receivable, net	93,908	50,535	25,554
Accounts receivable due from related parties, net	1,445	293	4,089
Other receivables	332	9,771	6,625
Current inventories	58,259	60,417	53,368
Prepayments	28,070	22,671	20,533
Other current assets	4,782	12,011	1,642
Total current assets	683,653	465,543	586,113
Non-current assets			
Non-current financial assets at fair value through other comprehensive income	169,354	137,581	110,221
Property, plant and equipment	555,484	424,892	365,432
Right-of-use assets	56,109	0	0
Intangible assets	83,034	12,993	13,773
Deferred tax assets	73,467	69,438	63,256
Other non-current assets	8,970	8,268	43,028
Total non-current assets	946,418	653,172	595,710
Total assets	1,630,071	1,118,715	1,181,823
Current liabilities			
Current contract liabilities	70,465	44,199	5,257
Accounts payable	31,876	39,887	15,007
Other payables	65,290	95,610	72,312
Other payables to related parties	13,155	19	0
Current lease liabilities	14,344	0	0
Other current liabilities	9,372	336	331
Total current liabilities	204,502	180,051	92,907
Non-current liabilities			
Non-current portion of non-current borrowings	96,775	0	0
Deferred tax liabilities	6,978	1,765	0
Non-current lease liabilities	40,637	0	0
Other non-current liabilities	30,201	29,884	41,124
Total non-current liabilities	174,591	31,649	41,124
Total liabilities	379,093	211,700	134,031
Share capital			
Ordinary share	1,279,545	1,099,545	1,121,545
Total share capital	1,279,545	1,099,545	1,121,545
Capital surplus			
Capital surplus, additional paid-in capital	221,400	261,501	266,733
Capital surplus, treasury share transactions	0	0	2,812
Capital surplus, employee share options	39,508	39,285	36,339
Total capital surplus	260,908	300,786	305,884
Retained earnings			
Unappropriated retained earnings (accumulated deficit)	-340,650	-519,697	-315,247
Total retained earnings	-340,650	-519,697	-315,247
Other equity interest			
Unrealised gains (losses) from financial assets measured at fair value through other comprehensive income	51,175	26,381	23,221
Total other equity interest	51,175	26,381	23,221
Treasury shares	0	0	-87,611
Total equity	1,250,978	907,015	1,047,792
Total liabilities and equity	1,630,071	1,118,715	1,181,823
Number of share capital awaiting retirement	0	0	0
Equivalent issue shares of advance receipts for ordinary share	0	0	0
Number of shares in entity held by entity and by its subsidiaries	0	0	2,200,000

Provided by: Mycenax Biotech Inc.

Financial year: Yearly

Unit: NT\$ thousand

Accounting Title	2019/2nd	2018/2nd	2019/01/01To2019/06/30	2018/01/01To2018/06/30
Income Statement				
Total operating revenue	114,928	48,440	181,310	65,887
Total operating costs	65,401	43,792	108,511	84,538
Gross profit (loss) from operations	49,527	4,648	72,799	-18,651
Gross profit (loss) from operations	49,527	4,648	72,799	-18,651
Operating expenses				
Selling expenses	14,714	3,482	18,162	5,837
Administrative expenses	10,021	9,675	18,170	18,522
Research and development expenses	60,419	70,436	130,291	105,284
Impairment loss (impairment gain and reversal of impairment loss) determined in accordance with IFRS 9	-707	-244	353	631
Total operating expenses	84,447	83,349	166,976	130,274
Net operating income (loss)	-34,920	-78,701	-94,177	-148,925
Non-operating income and expenses				
Total other income	1,848	8,295	5,261	9,294
Other gains and losses, net	1,058	15,026	2,160	7,441
Finance costs, net	534	74	1,000	148
Total non-operating income and expenses	2,372	23,247	6,421	16,587
Profit (loss) from continuing operations before tax	-32,548	-55,454	-87,756	-132,338
Total tax expense (income)	-2,254	120	-5,302	-6,514
Profit (loss) from continuing operations	-30,294	-55,574	-82,454	-125,824
Profit (loss)	-30,294	-55,574	-82,454	-125,824
Other comprehensive income				
Unrealised gains (losses) from investments in equity instruments measured at fair value through other comprehensive income	47,474	-5,569	31,772	-5,569
Income tax related to components of other comprehensive income that will not be reclassified to profit or loss	5,697	0	6,978	-46
Components of other comprehensive income that will not be reclassified to profit or loss	41,777	-5,569	24,794	-5,523
Other comprehensive income, net	41,777	-5,569	24,794	-5,523
Total comprehensive income	11,483	-61,143	-57,660	-131,347
Basic earnings per share				
Total basic earnings per share	-0.24	-0.51	-0.67	-1.14

Provided by: Mycenax Biotech Inc.

Financial year: Yearly

Unit: NT\$ thousand

Accounting Title	2019/01/01To2019/06/30	2018/01/01To2018/06/30
Statements of Cash Flows		
Cash flows from (used in) operating activities, indirect method		
Profit (loss) from continuing operations before tax	-87,756	-132,338
Profit (loss) before tax	-87,756	-132,338
Depreciation expense	53,958	36,454
Amortization expense	6,092	784
Expected credit loss (gain) / Provision (reversal of provision) for bad debt expense	353	631
Interest expense	1,000	148
Interest income	-1,720	-2,781
Share-based payments	223	6,483
Loss (gain) on disposal of property, plan and equipment	0	8
Impairment loss on non-financial assets	1,665	1,989
Total adjustments to reconcile profit (loss)	61,571	43,716
Decrease (increase) in contract assets	-2,087	0
Decrease (increase) in accounts receivable	-40,174	41,119
Decrease (increase) in accounts receivable due from related parties	-1,152	-2,556
Decrease (increase) in other receivable	9,530	-5,619
Decrease (increase) in inventories	493	-9,151
Decrease (increase) in prepayments	-5,234	-8,947
Decrease (increase) in other current assets	-2,633	-251
Total changes in operating assets	-41,257	14,595
Increase (decrease) in contract liabilities	21,948	3,374
Increase (decrease) in accounts payable	-16,157	5,440
Increase (decrease) in other payable	-23,252	-51,168
Increase (decrease) in other payable to related parties	36	-321
Increase (decrease) in other current liabilities	617	-727
Increase (decrease) in net defined benefit liability	-39	-29
Total changes in operating liabilities	-16,847	-43,431
Total changes in operating assets and liabilities	-58,104	-28,836
Total adjustments	3,467	14,880
Cash inflow (outflow) generated from operations	-84,289	-117,458
Interest paid	-1,160	0
Income taxes refund (paid)	-175	1,654
Net cash flows from (used in) operating activities	-85,624	-115,804
Cash flows from (used in) investing activities		
Proceeds from disposal of financial assets at amortised cost	59,126	168,669
Acquisition of property, plant and equipment	-125,454	-265
Proceeds from disposal of property, plant and equipment	0	124
Increase in refundable deposits	56	70
Acquisition of intangible assets	-897	-2,089
Decrease in other financial assets	10,000	9,108
Increase in prepayments for business facilities	-4,739	-45,526
Interest received	1,629	3,037
Other investing activities	-117,900	0
Net cash flows from (used in) investing activities	-178,179	133,128
Cash flows from (used in) financing activities		
Proceeds from long-term debt	108,000	0
Repayments of long-term debt	-2,806	0
Payments of lease liabilities	-8,569	0
Proceeds from issuing shares	401,400	0
Net cash flows from (used in) financing activities	498,025	0
Effect of exchange rate changes on cash and cash equivalents	0	0
Net increase (decrease) in cash and cash equivalents	234,222	17,324
Cash and cash equivalents at beginning of period	215,745	342,061
Cash and cash equivalents at end of period	449,967	359,385
Cash and cash equivalents reported in the statement of financial position	449,967	359,385
Other items qualifying for cash and cash equivalents under the definition of IAS 7	0	0

Provided by: Mycenax Biotech Inc.

Financial year: Yearly

Unit: NT\$ thousand

2019/06/30 Statement of Stockholders' Equity

Unit: NT\$ thousand

Accounting Title	Ordinary share	Total share capital	Capital surplus	Unappropriated retained earnings (accumulated deficit)	Total retained earnings	Unrealised gains (losses) on financial assets measured at fair value through other comprehensive income	Total other equity interest	Treasury shares	Total equity
Equity at beginning of period	1,099,545	1,099,545	300,786	-519,697	-519,697	26,381	26,381		907,015
Capital surplus used to offset accumulated deficits	0	0	-261,501		261,501	0	0		0
Profit (loss)	0	0	0	-82,454	-82,454	0	0		-82,454
Other comprehensive income	0	0	0	0	0	24,794	24,794		24,794
Total comprehensive income	0	0	0	-82,454	-82,454	24,794	24,794		-57,660
Issue of shares	180,000	180,000	221,400	0	0	0	0		401,400
Share-based payments	0	0	223	0	0	0	0		223
Total increase (decrease) in equity	180,000	180,000	-39,878	179,047	179,047	24,794	24,794		343,963
Equity at end of period	1,279,545	1,279,545	260,908	-340,650	-340,650	51,175	51,175		1,250,978

2018/06/30 Statement of Stockholders' Equity

Unit: NT\$ thousand

Accounting Title	Ordinary share	Advance receipts for share capital	Total share capital	Capital surplus	Unappropriated retained earnings (accumulated deficit)	Total retained earnings	Unrealised gains (losses) on financial assets measured at fair value through other comprehensive income	Total other equity interest	Treasury shares	Total equity
Equity at beginning of period	1,121,180	604	1,121,784	299,162	-189,469	-189,469	0	0	-87,611	1,143,866
Effects of retrospective application and retrospective restatement	0	0	0	0	0	0	28,790	28,790	0	28,790
Equity at beginning of period after adjustments	1,121,180	604	1,121,784	299,162	-189,469	-189,469	28,790	28,790	-87,611	1,172,656
Profit (loss)	0	0	0	0	-125,824	-125,824	0	0	0	-125,824
Other comprehensive income	0	0	0	0	46	46	-5,569	-5,569	0	-5,523
Total comprehensive income	0	0	0	0	-125,778	-125,778	-5,569	-5,569	0	-131,347
Share-based payments	365	-604	-239	6,722	0	0	0	0	0	6,483
Total increase (decrease) in equity	365	-604	-239	6,722	-125,778	-125,778	-5,569	-5,569	0	-124,864
Equity at end of period	1,121,545	0	1,121,545	305,884	-315,247	-315,247	23,221	23,221	-87,611	1,047,792